# General Session 7: Controversies in Screening and Surveillance in Colorectal Cancer

Complexities of Pathological Assessment:
Serrated Polyps/Adenomas

Carolyn Compton, MD, PhD
Professor of Life Sciences, ASU
Professor of Laboratory Medicine and Pathology, Mayo Clinic

#### **Learning Objectives**

After reviewing this material, the participant should be able to:

- Describe the pathological, endoscopic and molecular differences among the three types of serrated polyps
- Compare the relative prevalence rates and cancer risks of the three types of serrated polyps
- Describe the differences in surveillance and treatment approaches for serrated polyps (sporadic and syndromic)

#### **Outline**

- Classification of serrated polyps
- Pathogenesis and molecular alterations
- Dysplastic potential and cancer risk
- Controversies in pathological interpretation
- Surveillance and treatment approaches

#### What Are Serrated Polyps?

- Category of colonic polyp redefined in the last 15 years on the basis of pathological,
   molecular and clinical features
  - Hyperplastic polyps formerly thought to have no malignant potential
  - Serrated polyps are now viewed as a family of lesions with varying histopathological features and malignant potential
  - 30-35% of colorectal cancer arises from serrated polyps in a dysplasia-carcinoma sequence via an alternate pathway

#### Why Are Serrated Polyps Important?

- High frequency in right colon: missed on colonoscopy
- Flat or sessile morphology: easily overlooked on colonoscopy
- III-defined borders: incomplete resection
- Pathological interpretation variable
  - Unfamiliarity with serrated pathway lesions and progression
  - Under-diagnosis of serrated lesions with cancer risk
- Under-diagnosis of syndromic disease
- Precursors of most CIMP\* (either MSI or MSS) colorectal cancers
  - About a third of all CRC evolve through the serrated pathway
- Serrated morphology carcinoma is now a WHO subtype: frequent KRAS and BRAF mutations and poor prognosis

\* CpG island methylator phenotype

#### What Are Serrated Polyps?


- Defined histopathologically by a single dominant feature: the tufted growth pattern of the epithelium that gives the polyp glands an appearance described as:
  - Stellate
  - Saw-toothed
  - Serrated




serrated washer

#### Architecture: Serrated Polyp vs. Adenomatous Polyp

Serrated vs. straight gland profiles






#### Classification of Serrated Polyps (WHO 2010)

Serrate Subtype	Microscopic	Macroscopic	Dysplasia
Goblet cell hyperplastic polyp (GCHP)	Goblet cells Straight crypts Little serration	Flat Distal ≤5 mm	No
Microvesicular hyperplastic polyp (MVHP)	Fine mucin droplets Straight crypts Serration in 1/3-2/3 of glands	Flat Proximal ≤5 mm	No
Sessile serrated adenoma (SSA)	Dilated & distorted crypts L, J or anchor shaped crypts Serration throughout glands	Flat Mucinous "cap" Proximal Typically ≥1 cm	Yes
Traditional serrated adenoma (TSA)	Complex architecture Villous or filliform epithelial projections Eosinophilic cytoplasm	Pedunculated Distal ≥1 cm, often large	Yes


### **Serrated Polyp Types**


Goblet cell hyperplastic polyp ------




Sessile serrated adenoma ------

Traditional serrated adenoma ------









#### **Prevalence**

Serrated polyp type	Prevalence	
Hyperplastic polyps	80-90% of all serrated polyps	Very common
Sessile serrated adenomas	10-25% of all serrated polyps	Fairly common
Traditional serrated adenomas	1-2% of all serrated polyps	Rare


#### Controversies: MVHP vs. SSA

- Moderate intra-observer agreement/disagreement (κ = 0.56-0.63)\*
- Serrated polyps may have overlapping MVHP/SSA features
- Under-diagnosis of SSA (as a hyperplastic polyp) is common
- Minimum diagnostic criteria are controversial
  - If 2-3 adjacent crypts show SSA features, classified as an SSA (WHO)
  - Presence of one dilated crypt sufficient to classify as SSA (AGA)
- Cancer risk is related to dysplasia
  - Any SSA with conventional dysplasia is classified as "advanced" and should be considered equivalent to adenomatous polyp with high-grade dysplasia


\*Perfect agreement: K = 1

#### Controversies: "Mixed" (Serrated/Adenomatous) Polyps

- Appearance: abrupt transition or side-by-side co-localization of glands typical of SSA (with or without dysplasia) and glands with confluent dysplasia typical of adenomatous polyp
- Some authorities classify these as "mixed" polyp
- Others regard these as SSAs with HGD
- Either way, cancer risk is related to the presence of dysplasia




HGD in serrated glands



HGD in straight glands

#### Serrated Polyposis Syndrome (SPS)

- Rare syndrome defined by Burt and Jass, 2000
  - Formerly known as hyperplastic polyposis syndrome
- Multiple and/or large serrated polyps
  - At least 5 serrated polyps proximal to sigmoid, 2 being > 10mm
  - Any number of serrated polyps and 1<sup>st</sup> degree relative with syndrome
  - >20 serrated polyps distributed throughout the colon



lleocecal valve



#### **Serrated Polyposis Syndrome (SPS)**


- Increased CRC risk but degree of risk unclear
  - Published series: 25-70% of patients had CRC at diagnosis or follow-up
  - Lifetime risk of 50%
  - Cumulative risk of cancer: 2 -7% at 5 years (Carballal et al, Gut 2015)
- Surveillance: current recommendation = every year (WHO)
- Surgery warranted:
  - To prevent risk of progression
  - When carcinoma found
  - When endoscopic resection is unfeasible (lesions of large size or involving appendix or ileocecal valve)

#### **Serrated Polyps: Molecular Profiles**

#### Issues and implications:

- Hyperplastic polyps are true neoplasms with defined oncogene mutations
- MVHPs are precursors of SSAs
  - Association of MLH-1 hypermethylation and dysplasia suggests that MLH-1 hypermethylation is a late event with high risk of progression
- GCHPs are likely precursors of TSAs
  - Molecular characteristics and distal location suggest this


#### **Pathogenesis: Serrated Pathway**




CIMP = CpG island methylator phenotype MSI = microsatellite instability CIN = chromosomal instability

A-M Baket et al, Scientific Reports, 2015; 5 : 8654 | DOI: 10.1038.


# Molecular Progression: MVHP → SSA → Dysplastic SSA → MSI CRC




## Adenomatous vs. Serrated Pathway



#### **Serrated Pathways**





Geraint Williams, Pathology Department, Cardiff University

### **Surveillance for Serrated Polyps**

- Recommendations related to:
  - Type
  - Size
  - Number
  - Location

#### **Serrated Polyps: Surveillance Recommendations**

Serrated polyp	USMSTF / ACA 2012 Recommended interval	Expert Panel 2012 Recommended interval
Goblet cell HP	None	5 years If proximal and >5mm
Microvesicular HP	None	5 years If proximal and >5mm
Sessile SA/Polyp	5 years if < 10 mm 3 years if ≥ 10 mm	<ul> <li>5 years if &lt;10 mm</li> <li>3 years if ≥10 mm or any size and n≥3</li> <li>1-3 years if ≥10 mm and n≥2 or dysplasia</li> </ul>
Traditional SA	3 years	<ul> <li>5 years if &lt;10 mm</li> <li>3 years if ≥ 10mm and n≥2</li> </ul>

#### Serrated Polyps: Surveillance Recommendations

(Expert Opinion from Sweetser, Smyrk, Sugumar. Expert Rev Gastroenterol Hepatol 2011; 5: 627-35)

Lesion found	Surveillance interval
Serrated polyposis	1 year
Serrated polyp with any dysplasia	3 years
Serrated polyp proximal to the splenic flexure	3 years
Serrated polyp ≥10 mm	3 years
Serrated polyps <10 mm and distal to splenic flexure	10 years

#### **Summary**

- Serrated polyps represent a spectrum of neoplasms with overlapping histopathological features that may create a challenge for interpretation and precise classification
- Serrated adenomas may occur as sporadic or rarely syndromic lesions
- Serrated polyps with dysplasia are classified as adenomas and carry a significant cancer risk that necessitates increased surveillance
- Cancer risk is related to dysplasia as well as lesion location, size, and number
- Molecular pathogenesis differs from that of adenomatous polyps
- Resultant cancers have microsatellite instability rather than chromosomal instability

# General Session 7: Controversies in Screening and Surveillance in Colorectal Cancer

Complexities of Pathological Assessment: Serrated Polyps/Adenomas

Carolyn Compton, MD, PhD
Professor of Life Sciences, ASU
Professor of Laboratory Medicine and Pathology, Mayo Clinic